BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Analyst Price Forecast Suggests 87.91% Upside As of January 29, 2025, the average one-year price target for Beam Therapeutics is $48.72/share. The forecasts range from a low of $23.23 to a high of ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...

Mumbai-based Beams Fintech Fund, a homegrown private equity firm focused on investments in growth-stage financial services and software companies, has started initial preparations for its second PE ...

In the preceding three months, 4 analysts have released ratings for Beam Therapeutics BEAM, presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...